CELSR2 and central nervous system cancer: In CELSR2 KD glioma cells, suppressing GSK-3β activation using inhibitors induced downregulation of phosphorylated β-catenin and upregulation of unphosphorylated β-catenin which subsequently activated nuclear transcription and cell proliferation as shown by EdU labeling and cell cycle analysis.